newsfilter
← Latest News
GlobeNewswire·

Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights

Additional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven abstracts accepted at SSIEM highlight potential